Longeveron (LGVN)

• Market cap: $25.9M
• 1 day: -2.37%
• 5 days: 5.14%
• 1 month: 21.3%
• 3 months: -15.99%
• 6 months: 48.78%
• Year to date: 38.3%
• 1 year: -32.22%
• 5 years: -98.86%
• 10 years: -98.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Employees: 38